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ABSTRACT 21 
There are currently two major factors that have modified the epidemiology of 22 
Chagas disease in the last decades: climate change and migration flows. In this new 23 
scenario, there are new challenges to control and prevent T. cruzi infection in endemic 24 
countries, such as the control of a wider distribution of triatomine vectors or the 25 
reinforcement of vertical transmission programs.. In non-endemic areas, few countries 26 
are aware of the emergence of this new disease and have established changes in their 27 
health systems. To address this new public health challenge, the priorities should be 28 
control programs to avoid new cases of T. cruzi infection acquired through vertical 29 
transmission, blood transfusion or organ transplant.  30 
In both, endemic and non-endemic areas, the international community and all the 31 
actors involved in Chagas disease must join efforts mainly in two directions: better 32 
management of the infection in affected individuals and more research to cover the 33 
knowledge gap mainly in physiopathology, diagnosis and treatment. 34 
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1.- Introduction: the keys of disease globalization in the XXI century 44 
Chagas disease, caused by Trypanosoma cruzi parasite, was originally described 45 
as an endemic disease focused in populations living in poor rural areas of Latin 46 
American countries.  47 
From the ecological point of view, there have been two major factors that have modified 48 
the epidemiology of the disease: climate change and human migration. Even if it is 49 
difficult to quantify the impact of climate change in vector borne disease transmission, 50 
altitude levels of the traditionally defined endemic areas , the wild cycle of triatomine  51 
and the vector-parasite  interaction can be modified due to global warming.[1,2]   52 
 53 
Moreover, anthropical factor, through various initiatives of vector control, add 54 
an important element to the epidemiological issue in endemic countries. 55 
Historically, migration has been the key factor in the dissemination of Chagas 56 
disease [3].  Recently, migrant flows have brought  infected individuals to Latin 57 
American urban areas and beyond the borders of Latin America, changing the 58 
epidemiology of the disease [4].   59 
The migratory flows between Latin American and European countries are not 60 
new. During the fifteenth century many European citizens migrated towards the 61 
Americas. This process continued until the fifties of the twentieth century, when Latin 62 
America became a region of origin of international migrants, being the United States 63 
and Europe the main receptors of Latin America migrants. This trend has continued 64 
until 2008, when due to the economic crisis the migratory flows from LA significantly 65 
decreased. United States is the main destination of Latin American migration with 66 
approximately 20.5 million Latin American immigrants living in the country, according 67 
to some estimates.[5] Today, around 3.5 million people from Latin American live in 68 
Europe.[6] In Europe, the distribution by country of Lain American migrants follows a 69 
patchy pattern, where certain few countries concentrate most of the Latin American 70 
migration. Spain, with over half of these migrants, is undoubtedly the most important 71 
recipient, followed by Italy, France, and United Kingdom.[7] 72 
 This initial distribution is changing due to the economic crisis and currently 73 
there is a redistribution of Latin American migration, especially from Spain to other 74 
European countries. [6] 75 
 One of the features that affect many Latin American immigrants today is the 76 
fact that the migration process does not stop with a single shift; quite often migrants 77 
look for job opportunities in three or more countries in relatively short periods of time. 78 
These frequent changes involve European and American countries, posing a challenge 79 
to the health care of these people. 80 
 81 
2.- New characteristics of Chagas disease in endemic countries 82 
Trypanosoma cruzi infection is a complex entity caused by a heterogeneous 83 
species of the parasite (T. cruzi) that implies a wide diversity of animals in the wild 84 
cycle, playing domestic animals an important epidemiological role in some areas.[8] 85 
The distribution of Chagas disease in endemic areas has been described as patchy and 86 
heterogeneous, involving different ecological niches and more than one hundred 87 
triatominae species, the vector of the disease.[9] Five triatomine vectors species (T. 88 
infestans, R. prolixus, T. dimidiata, P. megistus, and T. brasiliensis) have a major 89 
epidemiological importance,[10] and it seems that there is a close association between 90 
some triatomine vector species and some specific strains of T.cruzi.[11,12]  91 
The transmission of T. cruzi in humans can occur in in well-known ways, and 92 
several approaches of control have been developed. 93 
Vector transmission and programs of vector control 94 
The implementation of vector control programs started in the 90’s through 95 
several initiatives along the endemic countries has contributed to change dramatically 96 
the epidemiology of Chagas disease in Latin America.[13,14] The goal in most of these 97 
programs was the interruption of the domestic and peridomestic cycles of transmission 98 
through insecticide spraying. These programs - only useful for domiciliary vectors - 99 
have been successful in several countries:  Brazil, Uruguay and Chile have been 100 
declared free from disease transmission by T.infestans, as well as specific departments 101 
of several other countries. [15,16] Equally, Guatemala was certified as being free from 102 
disease transmission by Rhodnius prolixus, the main domiciliated vector for Chagas 103 
disease in Central America.[16] But the temporal action of insecticides is not 104 
permanent. As demonstrated by some authors, recolonisation of houses by sylvatic 105 
triatomine populations may explain some difficulties encountered in vector control.[17]  106 
Triatomine re-infestation is one of the major challenges in endemic areas, which 107 
oblige to maintain active the vector control programs.  The decentralization of vector 108 
control is still controversial, although it is one of the keys for a sustainable 109 
entomological surveillance. Selective control and surveillance strategies are required 110 
due to the risk of possible domiciliary re-infestations.[16]   111 
 Moreover, there are reports showing the emergence of insecticide resistance 112 
among triatominos.[18,19]  113 
Rural to urban migration 114 
In endemic countries, and mainly due to economic reasons, people living in rural 115 
areas moved to urban areas, increasing urbanization in periurban areas with poor 116 
hygienic conditions and where T.cruzi transmission can persist.[20]  117 
Increasing detection of T. cruzi infection cases transmitted by oral transmission 118 
Human oral infection is caused by ingestion of drinks or food contaminated with 119 
infected triatomine bugs or their feces. It has been rarely described up to now, but in the 120 
last years there has been an increase of new cases and outbreaks reported, mainly in 121 
wild environments [21] but also in urban areas. Several cases and outbreaks have been 122 
reported in Brazil, Venezuela, Colombia, Mexico, Argentina and Bolivia. [22-26] 123 
Vertical transmission: the lack of surveillance programs 124 
Vertical transmission of Chagas disease is one the main challenges of health in endemic 125 
countries,[27,28] and it is not well managed yet. Due to the success of the programs of 126 
vector and blood bank control, congenital transmission has obtained increasing 127 
epidemiological importance.[29] Rates of congenital T.cruzi transmission range from 128 
0%-28.6%,[30] and the WHO estimated number of new cases of congenital T. cruzi 129 
infection is around  8.668  cases per year. [31]    130 
 131 
Successful blood banks control in Latin America countries 132 
Specific screening for T. cruzi in blood banks has been improved successfully in 133 
all Latin-American countries in the last years, with a coverage close to 100% [32,33]  134 
 135 
3.- Chagas as emerging disease in non-endemic countries 136 
As mentioned before, in non-endemic countries new migration flows have been 137 
the key for the emergence of Chagas disease in areas where it was not previously 138 
present. The importance of Chagas disease in this new scenario is directly related to the 139 
volume of migration flows received by each host country and also related to the specific 140 
origin of migrants received, since the distribution of Chagas disease is not homogeneous 141 
within endemic countries. 142 
Europe and the United States have been the main recipients of Latin-American 143 
migration [3,33], and due to the current economic crisis some trends of migrant 144 
dispersion among European countries have been detected. 145 
It is estimated that in Europe there are between 68.000 and 123.000 infected 146 
people with T. cruzi, most of them living in Spain. However, until 2009 only 4.290 147 
cases have been reported. [4,35]   148 
In the United States, based on population figures from countries where Chagas 149 
disease is endemic, it is estimated that in 2011 there were about 300.000 people infected 150 
with T.cruzi.[34]  151 
In other countries with Latin American migration (Canada, Japan, Australia, 152 
other European countries) the number of people infected by T. cruzi ranges from 140 153 
(Austria) to over 12000 (England).[4,35,36] 154 
In non-endemic countries T.cruzi transmission occurs through blood transfusion 155 
and organ transplants from infected donors and from infected mothers to their children 156 
as well. 157 
Blood banks control strategies in non-endemic countries 158 
Few studies have been conducted in blood banks in non-endemic countries to 159 
assess the risk of transmission in blood banks. In Spain, one study showed that 0.62% of 160 
the Latin American donors (N= 1172) were positive for Chagas disease, but the 161 
percentage increased (10%) when only Bolivian migrants were considered.[37]   In 162 
other studies between 1% and 5% of blood donors were detected to be positive for 163 
Chagas disease in the U.S., Canada and Germany [38-40]  164 
Additionally, several cases of Chagas disease transmission in blood and 165 
transplants recipients have been reported in Europe and the United States [41-46] In 166 
Spain, universal blood donation screening for T. cruzi began in 2005 and in the U.S. in 167 
2007. In Europe only four more countries (France, Switzerland, United Kingdom and 168 
Sweden) have implemented effective measures to control risk of Chagas disease 169 
infection via blood transfusion.[47-49]   170 
A “new” route of transmission: organ transplantation 171 
Organ transplantation is more frequent in non-endemic than in endemic 172 
countries, and the new era of organ transplantation has opened another route of 173 
transmission of the parasite. The management of this clinical condition is especially 174 
important while immunosuppression is mandatory in the context of organ transplant.   175 
Several guidelines in endemic and non-endemic countries have been published for this 176 
new scenario.[50,52]  177 
Non-endemic countries becoming “endemic” countries: vertical transmission 178 
The risk of mother-to-child transmission is of concern in non-endemic countries. 179 
In a study performed in Spain, the rate of prevalence of T. cruzi in Latin American 180 
pregnant women (N= 1350) was 3.4% (27% in Bolivian mothers), with 7.3% of infected 181 
newborns.[53]   182 
In Europe and the United States, respectively, it is estimated that each year 183 
between 20 to 183, and 63 to 115 of newborns are infected with T. cruzi [33,34].  In 184 
fact, several cases of vertical transmission have already been identified in Europe.[53-185 
59] 186 
In Spain, a study showed that doing a screening in pregnant women for early 187 
detection and treatment to children infected by T. cruzi was cost-effective.[60]  188 
Following epidemiological and economic data, some regions of European 189 
countries, particularly Catalonia, Valencia, Galicia and more recently Andalucía (Spain) 190 
and Tuscany (Italy) have already approved official control measures in pregnant women 191 
at risk of T.cruzi infection and the early control of newborns from Chagas positive 192 
mothers.[61-63]  193 
Also in Europe, there are some other punctual initiatives from some centers for 194 
the control of newborns whose mothers are infected with T. cruzi. [49] Due to the high 195 
efficacy of specific T. cruzi treatment in newborns (of nearly 100%), programs for the 196 
control of Chagas disease via congenital transmission should be implemented in all 197 
countries to screen pregnant women coming from endemic areas with the objective of 198 
early treating the infected newborns.  199 
 200 
4.- Challenges on Chagas disease management in this new global scenario. 201 
Despite being globalized, Chagas disease remains one of the 17 neglected 202 
tropical diseases declared by the World Health Organization. Chagas disease has a 203 
significant economic impact. The global costs for Chagas disease have been estimated 204 
in  $7.19  billion per year, similar or even higher to those of other important diseases. 205 
[64] 206 
Vector control programs and oral transmission of Chagas disease are specific 207 
challenges for endemic countries, although due to human migration the repercussion of 208 
the success or failure of such programs goes beyond the Americas. Although endemic 209 
countries have direct responsibility for maintaining appropriate vector control programs, 210 
strengthening such programs is a major global challenge in which international 211 
community should be involved.  212 
Other challenges on Chagas disease are universal, mainly to improve control 213 
programs of vertical transmission in endemic areas, and to develop such programs in 214 
non-endemic countries. Endemic and many of the newly affected countries are 215 
registering cases of the disease transmitted congenitally. However, few countries are 216 
aware of the emergence of this new disease and few have established changes in their 217 
health system to address this new challenge for public health.[49] Despite the clinical, 218 
economic and epidemiological data available, effective vertical transmission control 219 
programs are not in place both in most endemic and non-endemic countries. [49] 220 
As a neglected disease, there are several gaps in the knowledge of crucial points 221 
in Chagas disease: the life cycle of T.cruzi in human hosts, the ecology of sylvatic 222 
cycle, the mechanisms of action of drugs against the parasite and the keys to improve 223 
the accessibility of the patients to the health systems. Funding for Chagas disease in 224 
2012 was 31.7 US$ million, which represents around 1% of total R&D funding spent on 225 
neglected diseases globally.[65]  226 
In this scenario, care of people with Chagas disease has been hampered by several 227 
factors. Here, we want to highlight some of them: the adverse events caused by the only 228 
two useful drugs against T. cruzi, the lack of early biomarkers of therapeutic efficacy 229 
and, above all, the importance given to the autoimmune theory of the disease that has 230 
prevailed for many years.  For years, health professionals have been trained in the belief 231 
that Chagas disease had no treatment and in the fear of giving the specific treatment due 232 
to the high rates of adverse events.  Other consequences of the lack of medical care are 233 
that patients carry the social stigma and negative psychological and economic effects of 234 
having an incurable disease.  235 
“The economic effects and the complexity of medical care are most evident in the more 236 
advanced stages of the disease (pacemakers, defibrillators, colon surgery ... ) , and in 237 
these cases it is not always possible to give the required care , either by economic or 238 
geographical reasons”. 239 
Moreover, research for new and better drugs have been slowed or forgotten for years 240 
until very recently.[66] 241 
In non-endemic countries, there are other important factors relating to the care of people 242 
affected. One of them is the lack of knowledge about the disease of many health 243 
professionals. This is aggravated by the change of migration patterns within or between 244 
countries when migrants are forced to move in search of better job opportunities and 245 
also for the wide diversity and poor specificity of symptoms of Chagas disease. Another 246 
problem relates to the policies of some governments to restrict the access of immigrants 247 
to health systems. .[6]  248 
In order to overcome these limitations in patients’ treatment, it is important to consider 249 
that: a) adverse events of antiparasitic drugs against T.cruzi are frequent. Even most of 250 
them are minor, a considerable percentage of treated patients suffer from adverse events 251 
and there is a need for monitoring patients closely during the treatment;[67,68] b) 252 
antiparasitic treatment  provided  to young women prevent further cases of congenital 253 
Chagas disease;[69] c) benznidazole induce a persistent negativization of the peripheral 254 
parasitemia in around 80% of treated patients 12 months after treatment.[70-72]; d) 255 
even if evidences with good clinical outcomes are lacking, there is a clinical benefit in 256 
treating patients .[73] ; e) the training of health professionals is vital for good patient 257 
care; f) to integrate the care of patients with Chagas disease into the primary  health 258 
programs is probably the most effective strategy in both, endemic and non-endemic 259 
countries.  260 
 261 
5.- Conclusions. 262 
The confluence of a disease influenced by changes in ecology and epidemiology, 263 
with a long asymptomatic phase, not clearly perceived as being related to infection, and 264 
affecting marginalized populations, has resulted in a silent public health crisis. [74] 265 
For facing this challenging disease, the international community and all the 266 
actors that play a role against Chagas disease must join efforts. There are precedents, 267 
such as the success of vector control programs, which indicate that when various actors 268 
come together to arrange a common and clear goal, this can be achieved. [75] 269 
In fact, a multidisciplinary approach is essential to address a health problem that is 270 
multifaceted, which includes the coordination of various control programs (vector , 271 
vertical , blood banks , transplant ), and the attention to affected people (primary care, 272 
different specialists) . Moreover, the decision makers must decide priorities within their 273 
competence in face of other health problems and coordinate with professionals working 274 
in the field and with the people affected.  275 
In 2012, a community of international partners endorsed the London Declaration 276 
on Neglected Tropical Diseases (NTDs).[76] This initiative, which calls to coordinate 277 
efforts to eliminate or control 10 NTDs, including Chagas disease, drew a new scenario 278 
of possibilities until 2020. However, few years after the initiative it seems that little 279 
have been done and that the defined goals need to be revised.[77]  280 
 281 
 282 
 283 
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